Cytokinetics Inc

• Country

  United States of America

• Sector

  Health Care

• Industry group

  Pharmaceuticals, Biotechnology & Life Sciences

• Industry

  Biotechnology

• Sub-sector

  Health Care

• Capitalization (millions of $)

  7483.4

• Ticker

  CYTK.O

• ISIN

  US23282W6057

• IPO date

  2004-04-29

• Availability on Russian exchanges

  Yes

• Reporting for

  2024-02-28

• Date fact. publication of reports

  2023-12-31

Cytokinetics, Incorporated is a late-stage biopharmaceutical company that is focused on discovering, developing and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases. The Company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. The Company is conducting METEORIC-HF, a second Phase III clinical trial of omecamtiv mecarbil. It is also developing aficamten, a cardiac myosin inhibitor, for the potential treatment of HCM. The Company also conducts research and development on novel treatments for disorders involving muscle function beyond muscle contractility. The Company’s lead drug candidates in clinical development are omecamtiv mecarbil, a cardiac myosin activator; CK-136, a cardiac troponin activator; reldesemtiv, a fast-skeletal muscle troponin activator (FSTA) and CK-3773274 (CK-274), a cardiac myosin inhibitor.